

Reiji Fukano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4352858/publications.pdf>

Version: 2024-02-01

15
papers

233
citations

1163065

8
h-index

1199563

12
g-index

15
all docs

15
docs citations

15
times ranked

436
citing authors

#	ARTICLE	IF	CITATIONS
1	Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. <i>Cancer Science</i> , 2020, 111, 4540-4547.	3.9	50
2	Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. <i>Pediatric Blood and Cancer</i> , 2010, 54, 212-215.	1.5	43
3	Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan. <i>British Journal of Haematology</i> , 2015, 168, 557-563.	2.5	37
4	Modeling and targeting of erythroleukemia by hematopoietic genome editing. <i>Blood</i> , 2021, 137, 1628-1640.	1.4	25
5	Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. <i>Pediatric Blood and Cancer</i> , 2016, 63, 451-457.	1.5	20
6	Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. <i>International Journal of Hematology</i> , 2018, 107, 244-250.	1.6	20
7	Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma. <i>International Journal of Hematology</i> , 2019, 110, 723-728.	1.6	9
8	Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial. <i>Nagoya Journal of Medical Science</i> , 2017, 79, 407-413.	0.3	9
9	Treatment of pediatric lymphoma in Japan: Current status and plans for the future. <i>Pediatrics International</i> , 2015, 57, 523-534.	0.5	8
10	The effect of graft-versus-host disease on outcomes after allogeneic stem cell transplantation for refractory lymphoblastic lymphoma in children and young adults. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28129.	1.5	5
11	Serum soluble ST2 as a marker of renal scar in pediatric upper urinary tract infection. <i>Cytokine</i> , 2019, 120, 258-263.	3.2	4
12	Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG). <i>British Journal of Haematology</i> , 2021, 194, 718-729.	2.5	3
13	Surge of serum interleukin-2 level in a Japanese patient with cytarabine syndrome. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28131.	1.5	0
14	Prognosis of pediatric patients with anicteric and late-onset sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28412.	1.5	0
15	G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL. <i>Blood Advances</i> , 2022, , .	5.2	0